» Articles » PMID: 20558158

Silencing of the PP2A Catalytic Subunit Causes HER-2/neu Positive Breast Cancer Cells to Undergo Apoptosis

Overview
Journal Exp Cell Res
Specialty Cell Biology
Date 2010 Jun 19
PMID 20558158
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Protein phosphatase 2A (PP2A), in its activated form as a phosphatase, is a tumour suppressor. However, when PP2A is phosphorylated at the tyrosine residue (pY307), it loses its phosphatase activity and becomes inactivated. In our previous study, we found a higher expression of pY307-PP2A in HER-2/neu positive breast tumour samples and significantly correlated to tumour progression, and in this context, it could function as a proto-oncogene. The above and subsequent findings led us to postulate that the critical role of PP2A in maintaining the balance between cell survival and cell death may be linked to its phosphorylation status at its Y307 residue. Hence, we further investigated the effects of knocking down the PP2A catalytic subunit which contains the Y307 amino acid residue in two HER-2/neu positive breast cancer cell lines, BT474 and SKBR3. We showed that this causes the silenced HER-2/neu breast cancer cells to undergo apoptosis and furthermore, that such apoptosis is mediated by p38 MAPK-caspase 3/PARP activation. Understanding the role of PP2A in HER2/neu positive cells might thus provide insight into new targets for breast cancer therapy.

Citing Articles

Quantum-based modeling implies that bidentate Arg-substrate binding enhances serine/threonine protein phosphatase-2A(PPP2R5D/PPP2R1A/PPP2CA)-mediated dephosphorylation.

Salter E, Wierzbicki A, Honkanen R, Swingle M Front Cell Dev Biol. 2023; 11:1141804.

PMID: 37377738 PMC: 10291244. DOI: 10.3389/fcell.2023.1141804.


PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.

Zhao H, Li D, Zhang B, Qi Y, Diao Y, Zhen Y Molecules. 2017; 22(12).

PMID: 29261144 PMC: 6149800. DOI: 10.3390/molecules22122277.


Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.

Zhao M, Howard E, Parris A, Guo Z, Zhao Q, Ma Z Oncotarget. 2017; 8(35):58847-58864.

PMID: 28938602 PMC: 5601698. DOI: 10.18632/oncotarget.19375.


ZEB1 Upregulates VEGF Expression and Stimulates Angiogenesis in Breast Cancer.

Liu L, Tong Q, Liu S, Cui J, Zhang Q, Sun W PLoS One. 2016; 11(2):e0148774.

PMID: 26882471 PMC: 4755590. DOI: 10.1371/journal.pone.0148774.


Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work?.

De P, Carlson J, Leyland-Jones B, Dey N Am J Cancer Res. 2015; 5(9):2872-91.

PMID: 26609493 PMC: 4633914.